The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
CD4+T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Open accessAbstract
CD4+T cells can eliminate tumor cells in vivo in the absence of CD8+T cells. We have CD4+T cells specific for a MHC class II-restricted, tumor-specific peptide derived from a mutant ribosomal protein expressed by the UV light-induced tumor 6132A-PRO. By using neutralizing mAb specific for murine IFN-γ and adoptive transfer of CD4+T cells into severe combined immunodeficient mice, we show that anti-IFN-γ treatment abolishes the CD4+T cell-mediated rejection of the tumor cells in vivo. The tumor cells were MHC class II negative, and IFN-γ did not induce MHC class II expression in vitro. Therefore, the tumor-specific antigenic peptide must be presented by host cells and not the tumor cells. Tumor cells transduced to secrete IFN-γ had a markedly reduced growth rate in severe combined immunodeficient mice, but IFN-γ did not inhibit the growth of the tumor cells in vitro. Furthermore, tumor cells stably expressing a dominant-negative truncated form of the murine IFN-γ receptor α chain, and therefore insensitive to IFN-γ, nevertheless were rejected by the adoptively transferred CD4+T cells. Thus, host cells, and not tumor cells, seem to be the target of IFN-γ. Together, these results show that CD4+T cells can eliminate IFN-γ-insensitive, MHC class II-negative cancer cells by an indirect mechanism that depends on IFN-γ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Fleiss, J. L., & Agresti, A. (1991) · Journal of the American Statistical Association · doi:10.2307/2290537 · Cited by 2,641
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,771
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
The Logic of Inductive Inference
Fisher, R. A. (1935) · Journal of the Royal Statistical Society · doi:10.2307/2342435 · Cited by 1,265
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,157
Xie, Q. W., Whisnant, R., & Nathan, C. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1779 · Cited by 1,118
Cherwinski, H. M., Schumacher, J. H., Brown, K. D., & Mosmann, T. R. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1229 · Cited by 1,036
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Luster, A. D., Unkeless, J. C., & Ravetch, J. V. (1985) · Nature · doi:10.1038/315672a0 · Cited by 944
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Self-citationInterferon-γ: Biology and Role in Pathogenesis
Billiau, A. (1996) · Advances in Immunology · doi:10.1016/s0065-2776(08)60428-9 · Cited by 433
Ohmori, Y., Schreiber, R. D., & Hamilton, T. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14899 · Cited by 413
Self-citationCoughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Liu, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80585-3 · Cited by 324
Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.3.952 · Cited by 312
Farber, J. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5238 · Cited by 298
Greenberg, P. D., Kern, D. E., & Cheever, M. A. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1122 · Cited by 292
Mig, the Monokine Induced By Interferon-γ, Promotes Tumor Necrosis In Vivo
Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., Burd, P. R., Yao, L., Gupta, G., Kanegane, C., & Tosato, G. (1997) · Blood · doi:10.1182/blood.v89.8.2635 · Cited by 246
Ohmori, Y., & Hamilton, T. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53303-2 · Cited by 243
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., T.Siegel, C., & Schreiber, H. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 241
Self-citationInterferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
Sgadari, C., Angiolillo, A. L., Cherney, B. W., Pike, S. E., Farber, J. M., Koniaris, L. G., Vanguri, P., Burd, P. R., Sheikh, N., Gupta, G., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13791 · Cited by 217
Folkman, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9064 · Cited by 198
Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells
Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G. P., Settlage, R. E., Shabanowitz, J., Rosenberg, S. A., Hunt, D. F., & Topalian, S. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.757 · Cited by 190
Knuth, A., Wölfel, T., Klehmann, E., Boon, T., & Meyer zum Büschenfelde, K. H. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2804 · Cited by 188
Horton, M. R., McKee, C. M., Bao, C., Liao, F., Farber, J. M., Hodge-DuFour, J., Puré, E., Oliver, B. L., Wright, T. M., & Noble, P. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.35088 · Cited by 173
Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12
Kanegane, C., Sgadari, C., Kanegane, H., Teruya‐Feldstein, J., Yao, L., Gupta, G. D., Farber, J. M., Liao, F., Liu, L., & Tosato, G. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.3.384 · Cited by 159
Fujiwara, H., Fukuzawa, M., Yoshioka, T., Nakajima, H., & Hamaoka, T. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.3.1671 · Cited by 158
Urban, J. L., Burton, R. C., Holland, J. M., Kripke, M. L., & Schreiber, H. W. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.2.557 · Cited by 135
Self-citationMultiple tumour-specific antigens expressed on a single tumour cell
Wortzel, R. D., Philipps, C., & Schreiber, H. W. (1983) · Nature · doi:10.1038/304165a0 · Cited by 108
Self-citationThe Role of B Cells for in Vivo T Cell Responses to a Friend Virus-Induced Leukemia
Schultz, K. R., Klarnet, J. P., Gieni, R. S., HayGlass, K. T., & Greenberg, P. D. (1990) · Science · doi:10.1126/science.2118273 · Cited by 97
Ward, P. L., Koeppen, H., Hurteau, T., Rowley, D. A., & Schreiber, H. W. (1990) · PubMed · Cited by 87
Self-citationDighe, A. S., Farrar, M. A., & Schreiber, R. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82246-3 · Cited by 50
Self-citationBiological Implications of HLA‐DR Expression in Tumours
Cabrera, T., Ruiz‐Cabello, F., & Garrido, F. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03584.x · Cited by 50
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.
Waes, C. V., Urban, J. L., Rothstein, J. L., Ward, P. L., & Schreiber, H. W. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.5.1547 · Cited by 37
Self-citationLeClaire, R. D., Basil, M., Pinson, D. M., Redick, M. L., Hunt, J. S., Zavodny, P. J., Pace, J. L., & Russell, S. W. (1992) · Journal of Leukocyte Biology · doi:10.1002/jlb.51.5.507 · Cited by 19
Frey, A. B. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3841 · Cited by 9
Cited by
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Self-citationType I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Self-citationAdvances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Metadata
- Authors
- Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., & Schreiber, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-07-20
- Volume
- 96
- Issue
- 15
- Pages
- 8633-8638
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2052363929
- Cited by
- 384
- References
- 38
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.